Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements
BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) — Aileron Therapeutics (Nasdaq:ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that it received written notice on November 28, 2022 from The Nasdaq Stock Market noting that Aileron has regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2), which requires the company to maintain a minimum closing bid price of $1.00 per share, and the matter is now closed. Nasdaq staff made this determination after Aileron’s closing bid price was above $1.00 per share for 10 consecutive business days from November 11, 2022 to November 25, 2022.
Related news for (ALRN)
- Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
- aileron therapeutics to present previously announced data from the phase 1b clinical trial evaluating low-dose lti-03 in idiopathic pulmonary fibrosis (ipf) at the 22nd international colloquium on lung and airway fibrosis
- aileron therapeutics completes enrollment in cohort 2 of the ongoing phase 1b clinical trial evaluating lti-03 in idiopathic pulmonary fibrosis (ipf)
- aileron therapeutics reports second quarter 2024 financial results and business highlights
- Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024